PPARγ and other PPAR agonists have various systemic adverse effects on heart failure [68], tumorigenesis, myalgia, and hepatic events [204], but they can hopefully be used to develop a safe drug for the treatment of fibrotic strictures. The gene discussed is PPARA; the disease is heart failure.